Clinical Trial Update: Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) [Phase 2]

View source ↗

Summary

Phase 2 trial update of durvalumab in frail and elderly patients with metastatic non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Carcinoma, Non-Small-Cell Lung, Metastatic Lung Cancer | Phase 2 | Status: COMPLETED